Clinical Trials Browser

Neoplasms

NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

42 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT06731907 2026-05-26

MK-3475-01G

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

Phase 2 Recruiting

60 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07252739 2026-05-26

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05061550 2026-05-22

NeoCOAST-2

Phase 2 Recruiting

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

280 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06783647 2026-05-18

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Phase 2 Recruiting

230 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT06868836 2026-05-18

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Phase 2 Recruiting

78 enrolled

Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Recruiting

170 enrolled

Other solid neoplasm

Solid Tumors

NCT07098988 2026-05-13

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

107 enrolled

Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06448754 2026-05-12

eVOLVE-01

Phase 2 Recruiting

180 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-05-08

PALOMA-2

Phase 2 Recruiting

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2 Recruiting

570 enrolled

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05118854 2026-05-04

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Phase 2 Recruiting

27 enrolled

Thoracic

Lung Neoplasms

NCT05456256 2026-05-04

HARMONIC

Phase 2 Recruiting

90 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05358548 2026-04-30

ATATcH Alternating Treatment Plans for Advanced Cancer

Phase 2 Recruiting

150 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT07309952 2026-04-30

SACTION 2501

Phase 2 Recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03872661 2026-04-21

NIBCUN

Phase 2 Recruiting

36 enrolled

Thoracic

Lung Neoplasms

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

112 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07020065 2026-04-15

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Phase 2 Recruiting

156 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

162 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06745882 2026-04-02

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Phase 2 Recruiting

318 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05805631 2026-03-24

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Phase 2 Recruiting

23 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04253964 2026-03-19

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Phase 2 Recruiting

105 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

270 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Phase 2 Recruiting

15 enrolled

Neoplasms, Recurrence

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2 Recruiting

64 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

51 enrolled

Thoracic

Lung Neoplasms

NCT05715229 2026-02-18

G360-IIT

Phase 2 Recruiting

108 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06296745 2026-01-30

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Phase 2 Recruiting

36 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04966663 2025-12-18

ctDNA Lung RCT

Phase 2 Recruiting

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Phase 2 Recruiting

240 enrolled

Thoracic

First-line Advanced NSCLC Patients

NCT06246110 2025-11-12

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2 Recruiting

70 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04410796 2025-11-06

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Phase 2 Recruiting

571 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04991025 2025-10-20

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Phase 2 Recruiting

60 enrolled

Thoracic

Lung Neoplasms

NCT07122687 2025-09-30

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

170 enrolled

Thoracic

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

NCT07181499 2025-09-30

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Phase 2 Recruiting

28 enrolled

Thoracic

NSCLC

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT04105270 2025-09-11

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Phase 2 Recruiting

82 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT06364917 2025-09-03

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase 2 Recruiting

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06784791 2025-08-29

NEOpredict-EGF

Phase 2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06897046 2025-08-01

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04136535 2025-07-22

PCA

Phase 2 Recruiting

105 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06057935 2025-07-22

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Phase 2 Recruiting

64 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06969027 2025-07-04

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

Phase 2 Recruiting

84 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06318286 2025-05-25

PENINSULA

Phase 2 Recruiting

25 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06659042 2025-05-18

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Phase 2 Recruiting

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05742607 2025-05-16

MATISSE

Phase 2 Recruiting

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05281406 2025-02-21

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Phase 2 Recruiting

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Pan Tumor Rollover Study

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

MK-3475-01G

MK-3475-01E

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NeoCOAST-2

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

eVOLVE-01

PALOMA-2

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

HARMONIC

ATATcH Alternating Treatment Plans for Advanced Cancer

SACTION 2501

NIBCUN

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

IMMUNOLIFE2

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

VELOCITY-Lung

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

G360-IIT

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

ctDNA Lung RCT

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

VIRO-25

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NEOpredict-EGF

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

PCA

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

PENINSULA

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

MATISSE

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)